

Stephen J Nicholls Mbbs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7021970/publications.pdf>

Version: 2024-02-01

489
papers

40,536
citations

5268

83
h-index

2895

190
g-index

500
all docs

500
docs citations

500
times ranked

30049
citing authors

#	ARTICLE	IF	CITATIONS
1	Multimodality Intravascular Imaging of High-Risk Coronary Plaque. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 145-159.	5.3	35
2	Assessing the Impact of Colchicine on Coronary Plaque Phenotype After Myocardial Infarction with Optical Coherence Tomography: Rationale and Design of the COCOMO-ACS Study. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 1175-1186.	2.6	7
3	Coronary Atherosclerotic Plaque Regression. <i>Journal of the American College of Cardiology</i> , 2022, 79, 66-82.	2.8	44
4	Eukaryotic elongation factor 2 kinase regulates foam cell formation via translation of CD36. <i>FASEB Journal</i> , 2022, 36, e22154.	0.5	3
5	Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density) Lipoprotein Levels and Improves Cardiovascular Risk in Patients with Coronary Heart Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 227-237.	2.4	21
6	HbA1c, Coronary atheroma progression and cardiovascular outcomes. <i>American Journal of Preventive Cardiology</i> , 2022, 9, 100317.	3.0	4
7	Implementation and prospective evaluation of the Country Heart Attack Prevention model of care to improve attendance and completion of cardiac rehabilitation for patients with cardiovascular diseases living in rural Australia: a study protocol. <i>BMJ Open</i> , 2022, 12, e054558.	1.9	5
8	Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1308-1321.	5.3	137
9	Targeting triglycerides to lower residual cardiovascular risk. <i>Expert Review of Cardiovascular Therapy</i> , 2022, , 1-7.	1.5	2
10	Pro-Calcific Environment Impairs Ischaemia-Driven Angiogenesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3363.	4.1	0
11	3D-Printed Micro Lens for In Vivo Multimodal Microendoscopy. <i>Small</i> , 2022, 18, e2107032.	10.0	21
12	Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 709-711.	5.3	2
13	Elevated Lipoprotein(a) as a potential residual risk factor associated with lipid-rich coronary atheroma in patients with type 2 diabetes and coronary artery disease on statin treatment: Insights from the REASSURE-NIRS registry. <i>Atherosclerosis</i> , 2022, 349, 183-189.	0.8	12
14	Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity. <i>Journal of the American Heart Association</i> , 2022, 11, e024754.	3.7	13
15	Phenotypic Features of Coronary Atheroma in Diabetic and Nondiabetic Patients With Low-Density Lipoprotein Cholesterol ≤ 55 mg/dL. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1166-1169.	5.3	2
16	Optical coherence tomography in coronary atherosclerosis assessment and intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 684-703.	13.7	106
17	Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial. <i>American Heart Journal</i> , 2022, 251, 1-12.	2.7	4
18	Health literacy and long-term health outcomes following myocardial infarction: protocol for a multicentre, prospective cohort study (ENHEARTEN study). <i>BMJ Open</i> , 2022, 12, e060480.	1.9	2

#	ARTICLE	IF	CITATIONS
19	Integrated guidance to enhance the care of children and adolescents with familial hypercholesterolaemia: Practical advice for the community clinician. <i>Journal of Paediatrics and Child Health</i> , 2022, 58, 1297-1312.	0.8	6
20	New Cardiovascular Risk Assessment Techniques for Primary Prevention. <i>Journal of the American College of Cardiology</i> , 2022, 80, 373-387.	2.8	5
21	The Residual Lipid-Rich Coronary Atheroma Behind the Implanted Newer-Generation Drug-Eluting Stent and Future Stent-Related Event Risks. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1504-1515.	1.7	2
22	Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imaging. <i>American Journal of Preventive Cardiology</i> , 2022, 11, 100366.	3.0	12
23	Previous Pre-Eclampsia, Gestational Diabetes and Hypertension Place Women at High Cardiovascular Risk: But Do We Ask?. <i>Heart Lung and Circulation</i> , 2021, 30, 154-157.	0.4	8
24	Cardiovascular bioimaging of nitric oxide: Achievements, challenges, and the future. <i>Medicinal Research Reviews</i> , 2021, 41, 435-463.	10.5	21
25	Gender Differences in Healthy Lifestyle Adherence Following Percutaneous Coronary Intervention for Coronary Artery Disease. <i>Heart Lung and Circulation</i> , 2021, 30, e37-e40.	0.4	14
26	Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. <i>American Heart Journal</i> , 2021, 231, 121-127.	2.7	60
27	Oral Calcium Supplements Associate With Serial Coronary Calcification. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 259-268.	5.3	15
28	Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. <i>New England Journal of Medicine</i> , 2021, 384, 31-41.	27.0	162
29	Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia. <i>Heart Lung and Circulation</i> , 2021, 30, 324-349.	0.4	51
30	Women With Spontaneous Coronary Artery Dissection Are at Increased Risk of Iatrogenic Coronary Artery Dissection. <i>Heart Lung and Circulation</i> , 2021, 30, e23-e28.	0.4	6
31	Long-term outcomes following endovascular and surgical revascularization for peripheral artery disease: a propensity score-matched analysis. <i>European Heart Journal</i> , 2021, 43, 32-40.	2.2	19
32	Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 120-129.	1.7	41
33	Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial. <i>Atherosclerosis</i> , 2021, 320, 122-128.	0.8	45
34	Clinical predictors and sequelae of computed tomography defined leaflet thrombosis following transcatheter aortic valve replacement at medium-term follow-up. <i>Heart and Vessels</i> , 2021, 36, 1374-1383.	1.2	10
35	Elevated HDL-bound miR-181c-5p level is associated with diabetic vascular complications in Australian Aboriginal people. <i>Diabetologia</i> , 2021, 64, 1402-1411.	6.3	13
36	BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. <i>Cell</i> , 2021, 184, 2167-2182.e22.	28.9	131

#	ARTICLE	IF	CITATIONS
37	Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1334.	7.4	2
38	A systematic review and meta-analysis of gender differences in long-term mortality and cardiovascular events in peripheral artery disease. <i>Journal of Vascular Surgery</i> , 2021, 73, 1456-1465.e7.	1.1	27
39	Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians. <i>Internal Medicine Journal</i> , 2021, 51, 769-779.	0.8	4
40	The Emerging Role of CT-Based Imaging in Adipose Tissue and Coronary Inflammation. <i>Cells</i> , 2021, 10, 1196.	4.1	12
41	Omega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects. <i>Atherosclerosis</i> , 2021, 324, 27-37.	0.8	25
42	Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. <i>Cardiovascular Diabetology</i> , 2021, 20, 125.	6.8	11
43	Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100151.	3.0	3
44	Cost-Effectiveness of Coronary Artery Calcium Scoring in People With a Family History of Coronary Disease. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1206-1217.	5.3	18
45	Can CMR Elucidate the Cardiovascular Benefit of SGLT2 Inhibitors?. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1174-1176.	5.3	1
46	Surgical and percutaneous management of Aboriginal Australians with rheumatic heart disease: Timeliness and concordance between practice and guidelines. <i>International Journal of Cardiology</i> , 2021, 335, 80-84.	1.7	2
47	Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. <i>European Heart Journal</i> , 2021, 42, 4324-4332.	2.2	135
48	Protective lipid-lowering variants in healthy older individuals without coronary heart disease. <i>Open Heart</i> , 2021, 8, e001710.	2.3	1
49	Association Between Achieved Ω -3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk. <i>JAMA Cardiology</i> , 2021, 6, 910.	6.1	52
50	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021, 385, 1451-1461.	27.0	2,143
51	Impact of a coronary artery calcium-guided statin treatment protocol on cardiovascular risk at 12 months: Results from a pragmatic, randomised controlled trial. <i>Atherosclerosis</i> , 2021, 334, 57-65.	0.8	7
52	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021, 42, 700-710.	2.2	117
53	Plaque microstructures during metformin therapy in type 2 diabetic subjects with coronary artery disease: optical coherence tomography analysis. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 12, 0-0.	1.7	5
54	An update on emerging drugs for the treatment of hypercholesterolemia. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 363-369.	2.4	4

#	ARTICLE	IF	CITATIONS
55	The Impact of Cardiac Rehabilitation and Secondary Prevention Programs on 12-Month Clinical Outcomes: A Linked Data Analysis. <i>Heart Lung and Circulation</i> , 2020, 29, 475-482.	0.4	49
56	Quantitative and Qualitative Coronary Plaque Assessment Using Computed Tomography Coronary Angiography: A Comparison With Intravascular Ultrasound. <i>Heart Lung and Circulation</i> , 2020, 29, 883-893.	0.4	6
57	High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 11-18.	2.2	0
58	Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 30-38.	4.4	4
59	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020, 5, 217.	6.1	169
60	Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. <i>American Heart Journal</i> , 2020, 221, 60-66.	2.7	5
61	Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1091-1100.	1.8	61
62	The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE. <i>Diabetes Care</i> , 2020, 43, e22-e24.	8.6	9
63	Using genetics to guide treatment and drug development in cardiovascular medicine: time to reveal the proof in the pudding. <i>Cardiovascular Research</i> , 2020, 116, e30-e32.	3.8	1
64	Cholesterol crystal-induced coronary inflammation: Insights from optical coherence tomography and pericoronary adipose tissue computed tomography attenuation. <i>Journal of Cardiovascular Computed Tomography</i> , 2020, 14, 277-278.	1.3	6
65	Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy. <i>Journal of the American Heart Association</i> , 2020, 9, e014328.	3.7	11
66	Association of Serum Lipoprotein (a) Levels and Coronary Atheroma Volume by Intravascular Ultrasound. <i>Journal of the American Heart Association</i> , 2020, 9, e018023.	3.7	12
67	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2383-2392.	7.1	93
68	Progression of coronary atherosclerosis in patients without standard modifiable risk factors. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100116.	3.0	12
69	Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2268.	7.4	540
70	Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 837-851.	3.3	8
71	Coronary artery calcium scoring in cardiovascular risk assessment of people with family histories of early onset coronary artery disease. <i>Medical Journal of Australia</i> , 2020, 213, 170-177.	1.7	17
72	Ultrathin monolithic 3D printed optical coherence tomography endoscopy for preclinical and clinical use. <i>Light: Science and Applications</i> , 2020, 9, 124.	16.6	80

#	ARTICLE	IF	CITATIONS
73	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.	27.0	2,821
74	The role of intracoronary imaging in translational research. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 1480-1507.	1.7	3
75	C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV. <i>American Journal of Preventive Cardiology</i> , 2020, 3, 100091.	3.0	2
76	Tackling cardiometabolic risk in the Asia Pacific region. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100096.	3.0	5
77	Lack of Strategic Funding and Long-Term Job Security Threaten to Have Profound Effects on Cardiovascular Researcher Retention in Australia. <i>Heart Lung and Circulation</i> , 2020, 29, 1588-1595.	0.4	10
78	Translating evidence from clinical trials of omega-3 fatty acids to clinical practice. <i>Future Cardiology</i> , 2020, 16, 343-350.	1.2	0
79	Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000943.	2.8	15
80	The mystery of evacetrapib - why are CETP inhibitors failing?. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 127-130.	1.5	12
81	Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1565.	7.4	103
82	Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease. <i>JAMA Cardiology</i> , 2020, 5, 1136.	6.1	59
83	Genome-Wide Polygenic Score and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002767.	3.6	9
84	Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. <i>Diabetes Care</i> , 2020, 43, 1077-1084.	8.6	21
85	2-Year Outcomes After Stenting of Lipid-Rich and Nonrich Coronary Plaques. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1371-1382.	2.8	15
86	Progression of ultrasound plaque attenuation and low echogenicity associates with major adverse cardiovascular events. <i>European Heart Journal</i> , 2020, 41, 2965-2973.	2.2	19
87	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	2.2	776
88	The fish-oil paradox. <i>Current Opinion in Lipidology</i> , 2020, 31, 356-361.	2.7	5
89	Current and Emerging Therapies for Atherosclerosis. , 2020, , 71-88.		0
90	Comparison between different approaches to evaluate fibrous cap thickness in sequential OCT studies. <i>Minerva Cardiology and Angiology</i> , 2020, , .	0.7	3

#	ARTICLE	IF	CITATIONS
91	Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. <i>Lancet, The</i> , 2019, 394, 697-708.	13.7	67
92	Current state-of-play in spontaneous coronary artery dissection. <i>Cardiovascular Diagnosis and Therapy</i> , 2019, 9, 281-298.	1.7	21
93	Vascular calcification in response to pharmacological interventions. , 2019, , 181-189.		0
94	Chronic kidney disease and coronary atherosclerosis: evidences from intravascular imaging. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 707-716.	1.5	4
95	Plaque Calcification. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1902-1910.	2.4	43
96	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1381.	7.4	144
97	Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. <i>Atherosclerosis</i> , 2019, 290, 59-65.	0.8	30
98	Associations of ABCG1-mediated cholesterol efflux capacity with coronary artery lipid content assessed by near-infrared spectroscopy. <i>Cardiovascular Diagnosis and Therapy</i> , 2019, 9, 310-318.	1.7	9
99	Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. <i>American Heart Journal</i> , 2019, 217, 72-83.	2.7	45
100	Association of Triglyceride-Lowering <i>LPL</i> Variants and LDL-Câ€“Lowering <i>LDLR</i> Variants With Risk of Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 364.	7.4	460
101	Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 343-348.	2.2	7
102	Awareness of Familial Hypercholesterolemia Among Healthcare Providers Involved in the Management of Acute Coronary Syndrome in Victoria, Australia. <i>CJC Open</i> , 2019, 1, 168-172.	1.5	3
103	Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2819-2828.	2.8	64
104	The Keeping on Track Study: Exploring the Activity Levels and Utilization of Healthcare Services of Acute Coronary Syndrome (ACS) Patients in the First 30-Days after Discharge from Hospital. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 61.	2.9	6
105	Vasculogenic properties of adventitial Sca-1+CD45+ progenitor cells in mice: a potential source of vasa vasorum in atherosclerosis. <i>Scientific Reports</i> , 2019, 9, 7286.	3.3	18
106	Status of PCSK9 Monoclonal Antibodies in Australia. <i>Heart Lung and Circulation</i> , 2019, 28, 1571-1579.	0.4	9
107	Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 171-177.	2.0	9
108	The time for lipoprotein(a) based intervention has arrived: where will the light shine?. <i>Journal of Thoracic Disease</i> , 2019, 11, S433-S436.	1.4	3

#	ARTICLE	IF	CITATIONS
109	Serial Coronary Plaque Assessment Using Computed Tomography Coronary Angiography. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e008404.	2.6	11
110	The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors. <i>Current Cardiology Reports</i> , 2019, 21, 18.	2.9	6
111	Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2019, 4, 314.	6.1	79
112	Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiography. <i>Atherosclerosis</i> , 2019, 284, 24-30.	0.8	37
113	Mendelian Randomization Study of <i>ACLY</i> and Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2019, 380, 1033-1042.	27.0	216
114	Visit-to-Visit Blood Pressure Variability, Coronary Atheroma Progression, and Clinical Outcomes. <i>JAMA Cardiology</i> , 2019, 4, 437.	6.1	59
115	The Australian Cardiovascular Alliance "Towards an Integrated Whole-of-Nation Strategy to Address Our Major Health Burden. <i>Heart Lung and Circulation</i> , 2019, 28, 198-203.	0.4	9
116	A Novel Ruthenium-based Molecular Sensor to Detect Endothelial Nitric Oxide. <i>Scientific Reports</i> , 2019, 9, 1720.	3.3	8
117	Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High-Risk Vascular Disease: Insights From the ACCELERATE Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e013790.	3.7	3
118	The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 49-57.	2.2	31
119	Combining cholesterol-lowering strategies with imaging data: a visible benefit?. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 365-379.	1.8	1
120	Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 113-131.	2.2	4
121	Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 229-235.	2.2	0
122	HDL and cardiovascular disease. <i>Pathology</i> , 2019, 51, 142-147.	0.6	56
123	Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis. <i>Clinical Biochemistry</i> , 2019, 64, 24-29.	1.9	36
124	Examining adherence to activity monitoring devices to improve physical activity in adults with cardiovascular disease: A systematic review. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 382-397.	1.8	27
125	Inflammatory Markers and Novel Risk Factors. <i>Contemporary Cardiology</i> , 2019, , 87-98.	0.1	0
126	Treating Dyslipidemia in Type 2 Diabetes. <i>Cardiology Clinics</i> , 2018, 36, 233-239.	2.2	11

#	ARTICLE	IF	CITATIONS
127	High-Density Lipoprotein Infusions. <i>Cardiology Clinics</i> , 2018, 36, 311-315.	2.2	3
128	Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. <i>American Heart Journal</i> , 2018, 202, 89-96.	2.7	13
129	Evaluation of human coronary vasodilator function predicts future coronary atheroma progression. <i>Heart</i> , 2018, 104, 1439-1446.	2.9	1
130	Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Vulnerable Plaque Features With Statin Therapy in Diabetic Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1721-1723.	5.3	5
131	Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes. <i>European Heart Journal</i> , 2018, 39, 2551-2558.	2.2	61
132	Effectiveness of discharge education on outcomes in acute coronary syndrome patients: a systematic review protocol. <i>JB I Database of Systematic Reviews and Implementation Reports</i> , 2018, 16, 817-824.	1.7	3
133	Intravascular Ultrasound Studies of Plaque Progression and Regression. <i>Cardiology Clinics</i> , 2018, 36, 329-334.	2.2	0
134	Myeloperoxidase modification of high-density lipoprotein suppresses human endothelial cell proliferation and migration via inhibition of ERK1/2 and Akt activation. <i>Atherosclerosis</i> , 2018, 273, 75-83.	0.8	9
135	Lipidology. <i>Cardiology Clinics</i> , 2018, 36, xiii.	2.2	0
136	Advances in lipid-lowering therapy through gene-silencing technologies. <i>Nature Reviews Cardiology</i> , 2018, 15, 261-272.	13.7	101
137	Managing Dyslipidemia in Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 153-173.	3.2	24
138	Modeling Statin-Induced Reductions of Cardiovascular Events in Primary Prevention: A VOYAGER Meta-Analysis. <i>Cardiology</i> , 2018, 140, 30-34.	1.4	5
139	Mechanisms of coronary ischaemia in women: Are we any closer to deciphering the code?. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 717-718.	1.8	1
140	<i>ADCY9</i> Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease. <i>JAMA Cardiology</i> , 2018, 3, 401.	6.1	42
141	Lipid Lowering in Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1325.	7.4	6
142	Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2018, 3, 391.	6.1	65
143	Early life exposure to Chinese famine modifies the association between hypertension and cardiovascular disease. <i>Journal of Hypertension</i> , 2018, 36, 54-60.	0.5	68
144	Warfarin Use Is Associated With Progressive Coronary Arterial Calcification. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1315-1323.	5.3	44

#	ARTICLE	IF	CITATIONS
145	Three- and 6-month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drug-eluting stent: The ANCHOR study. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 435-443.	1.7	7
146	Rationale and design of a trial to personalize risk assessment in familial coronary artery disease. <i>American Heart Journal</i> , 2018, 199, 22-30.	2.7	14
147	Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2018, 3, 164.	6.1	68
148	Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 109-115.	2.2	92
149	P2-037: APABETALONE (AN EPIGENETIC BET-INHIBITOR SMALL MOLECULE) AND EFFECTS ON COGNITION IN DIABETES PATIENTS WITH CARDIOVASCULAR DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P680.	0.8	0
150	SP436 DESIGN FEATURES OF THE BETONMACE CHRONIC KIDNEY DISEASE SUB-STUDY; EFFECTS OF THE SELECTIVE BET-INHIBITOR APABETALONE ON KIDNEY FUNCTION AND MACE IN POST-ACS PATIENTS WITH ESTIMATED GLOMERULAR FILTRATION RATE BELOW 60 AND DIABETES. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i495-i495.	0.7	0
151	Tackling Cardiovascular Risk in Type 2 Diabetes: Does Baseline Glucose Control Matter?. <i>EClinicalMedicine</i> , 2018, 4-5, 6-7.	7.1	0
152	Extent of coronary atherosclerosis and arterial remodelling in women: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 405-413.	1.7	4
153	High-Density Lipoprotein "Targeted Therapies" Not Dead Yet? Reply. <i>JAMA Cardiology</i> , 2018, 3, 1255.	6.1	1
154	Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial. <i>Diabetes Care</i> , 2018, 41, 2603-2609.	8.6	19
155	Serial changes in vessel walls of renal arteries after catheter-based renal artery denervation: insights from volumetric computed tomography analysis. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018, Volume 11, 259-266.	1.8	1
156	Monitoring the Response to Statin Therapy. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1485-1486.	5.3	2
157	Translating Evidence of HDL and Plaque Regression. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1961-1968.	2.4	25
158	The Extent of Aortic Atherosclerosis Predicts the Occurrence, Severity, and Recovery of Acute Kidney Injury After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006367.	3.9	19
159	Medical and lifestyle management of peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2018, 68, 1595-1606.	1.1	44
160	Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. <i>Journal of the American Heart Association</i> , 2018, 7, e009778.	3.7	67
161	Effect of Evolocumab on Coronary Plaque Composition. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2012-2021.	2.8	95
162	Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors. <i>European Cardiology Review</i> , 2018, 13, 9.	2.2	1

#	ARTICLE	IF	CITATIONS
163	Induction of obesity impairs reverse cholesterol transport in ob/ob mice. PLoS ONE, 2018, 13, e0202102.	2.5	18
164	The regulation of miRNAs by reconstituted high-density lipoproteins in diabetes-impaired angiogenesis. Scientific Reports, 2018, 8, 13596.	3.3	22
165	High-Density Lipoproteins and Apolipoprotein A-I Improve Stent Biocompatibility. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1691-1701.	2.4	16
166	Effect of Serial Infusions of CER-001, a Pre-Î² High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial. JAMA Cardiology, 2018, 3, 815.	6.1	135
167	Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial. JAMA Cardiology, 2018, 3, 806.	6.1	129
168	Vitamin D and Cardiovascular Disease. Heart Lung and Circulation, 2018, 27, 903-906.	0.4	3
169	Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2522-2533.	3.6	7
170	The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications. International Journal of Molecular Sciences, 2018, 19, 1680.	4.1	41
171	Exploring the Roles of CREBRF and TRIM2 in the Regulation of Angiogenesis by High-Density Lipoproteins. International Journal of Molecular Sciences, 2018, 19, 1903.	4.1	16
172	The relationship between segmental wall shear stress and lipid core plaque derived from near-infrared spectroscopy. Atherosclerosis, 2018, 275, 68-73.	0.8	17
173	Coronary arterial calcification: A review of mechanisms, promoters and imaging. Trends in Cardiovascular Medicine, 2018, 28, 491-501.	4.9	68
174	VEGFR2 is activated by high-density lipoproteins and plays a key role in the proangiogenic action of HDL in ischemia. FASEB Journal, 2018, 32, 2911-2922.	0.5	10
175	Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clinical Cardiology, 2018, 41, 1281-1288.	1.8	151
176	Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. Diabetes Care, 2018, 41, 1792-1800.	8.6	25
177	CETP Inhibition and HDL Cholesterol: A Story of CV Risk or CV Benefit, or Both. Clinical Pharmacology and Therapeutics, 2018, 104, 297-300.	4.7	22
178	Adherence to activity monitoring devices or smartphone applications for improving physical activity in adults with cardiovascular disease: a systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports, 2018, 16, 1634-1642.	1.7	4
179	Using Imaging to Identify the High-Risk Diabetic Patient. JACC: Cardiovascular Imaging, 2017, 10, 459-460.	5.3	0
180	Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. Journal of the American Heart Association, 2017, 6, .	3.7	2

#	ARTICLE	IF	CITATIONS
181	What role for lipoprotein(a) in clinical practice?. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 487-489.	11.4	3
182	Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors. <i>Internal Medicine Journal</i> , 2017, 47, 856-865.	0.8	18
183	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	2.2	2,292
184	Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1691.	7.4	1
185	Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. <i>Atherosclerosis</i> , 2017, 261, 12-18.	0.8	32
186	PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook. <i>BioDrugs</i> , 2017, 31, 167-174.	4.6	14
187	Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 447-452.	2.2	2
188	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1933-1942.	27.0	593
189	Will genetic studies deliver the next generation of cardioprotective therapies?. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 489-491.	1.8	1
190	NSAID Use and Cardiovascular Disease—A Cautionary Tale. <i>Heart Lung and Circulation</i> , 2017, 26, 753-756.	0.4	3
191	Taking the lid off the pot on marijuana and cardiovascular disease. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1831-1832.	1.8	2
192	Rationally Designed Probe for Reversible Sensing of Zinc and Application in Cells. <i>ACS Omega</i> , 2017, 2, 6201-6210.	3.5	20
193	Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database. <i>Atherosclerosis</i> , 2017, 265, 54-59.	0.8	29
194	In vivo visualization of lipid coronary atheroma with intravascular near-infrared spectroscopy. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 775-785.	1.5	11
195	Implications of GLAGOV study. <i>Current Opinion in Lipidology</i> , 2017, 28, 465-469.	2.7	6
196	High-density lipoprotein cholesterol associated with change in coronary plaque lipid burden assessed by near infrared spectroscopy. <i>Atherosclerosis</i> , 2017, 265, 110-116.	0.8	15
197	Plaque burden, microstructures and compositions underachieving very low LDL-C levels. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 122-132.	2.3	7
198	An organic fluorophore-nanodiamond hybrid sensor for photostable imaging and orthogonal, on-demand biosensing. <i>Scientific Reports</i> , 2017, 7, 15967.	3.3	14

#	ARTICLE	IF	CITATIONS
199	Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. <i>Atherosclerosis</i> , 2017, 263, 137-144.	0.8	35
200	PCSK9 Inhibitors: Treating the Right Patients in Daily Practice. <i>Current Cardiology Reports</i> , 2017, 19, 66.	2.9	1
201	Heart failure after conventional metal-on-metal hip replacements. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2017, 88, 2-9.	3.3	28
202	Atrial fibrillation, progression of coronary atherosclerosis and myocardial infarction. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 373-381.	1.8	23
203	Intravascular Ultrasound and Near-Infrared Spectroscopic Characterization of Thin-Cap Fibroatheroma. <i>American Journal of Cardiology</i> , 2017, 119, 372-378.	1.6	13
204	Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 947.	7.4	247
205	Investigating the long-term legacy of statin therapy. <i>Journal of Thoracic Disease</i> , 2017, 9, 936-939.	1.4	5
206	Anacetrapib as a potential cardioprotective strategy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3497-3502.	4.3	9
207	The relationship between coronary artery distensibility and fractional flow reserve. <i>PLoS ONE</i> , 2017, 12, e0181824.	2.5	16
208	High-density lipoproteins attenuate high glucose-impaired endothelial cell signaling and functions: potential implications for improved vascular repair in diabetes. <i>Cardiovascular Diabetology</i> , 2017, 16, 121.	6.8	17
209	Lipid Lowering Therapy to Modify Plaque Microstructures:. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 360-372.	2.0	7
210	Infusional high-density lipoproteins therapies as a novel strategy for treating atherosclerosis. <i>Archives of Medical Science</i> , 2017, 1, 210-214.	0.9	4
211	Design of the Familial Hypercholesterolaemia Australasia Network Registry: Creating Opportunities for Greater International Collaboration. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 1075-1084.	2.0	29
212	Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, 45-51.	1.7	49
213	Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, 252-263.	1.7	42
214	Results of the GLAGOV trial. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, e1-e5.	1.3	9
215	Noninvasive Assessment of Cardiopulmonary Reserve: Toward Early Detection of Pulmonary Vascular Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 398-401.	5.6	5
216	Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: from ASSERT to SUSTAIN and beyond. <i>Archives of Medical Science</i> , 2016, 6, 1302-1307.	0.9	14

#	ARTICLE	IF	CITATIONS
217	Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies. <i>Cardiovascular Diagnosis and Therapy</i> , 2016, 6, 282-303.	1.7	13
218	Cellular Therapy for Heart Failure. <i>Current Cardiology Reviews</i> , 2016, 12, 195-215.	1.5	23
219	Hypertriglyceridemia and Cardiovascular Diseases: Revisited. <i>Korean Circulation Journal</i> , 2016, 46, 135.	1.9	39
220	Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events. <i>American Journal of Cardiology</i> , 2016, 118, 647-655.	1.6	21
221	Using whispering gallery mode micro lasers for biosensing within undiluted serum. <i>Proceedings of SPIE</i> , 2016, , .	0.8	2
222	Biosensors for detecting stress in developing embryos. <i>Proceedings of SPIE</i> , 2016, , .	0.8	0
223	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). <i>American Heart Journal</i> , 2016, 176, 83-92.	2.7	45
224	Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. <i>Journal of Clinical Lipidology</i> , 2016, 10, 519-527.e4.	1.5	42
225	A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. <i>American Journal of Cardiology</i> , 2016, 117, 1444-1448.	1.6	78
226	CETP Inhibition in CVD Prevention: an Actual Appraisal. <i>Current Cardiology Reports</i> , 2016, 18, 43.	2.9	14
227	Focusing light on the vulnerable plaque. <i>Nature Reviews Cardiology</i> , 2016, 13, 253-255.	13.7	5
228	Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes. <i>Heart Lung and Circulation</i> , 2016, 25, 1051-1054.	0.4	0
229	Comparing Coronary Atheroma Progression Rates and Coronary Events in the United States, Canada, Latin America, and Europe. <i>American Journal of Cardiology</i> , 2016, 118, 1616-1623.	1.6	4
230	Sharing Data from Cardiovascular Clinical Trials – A Proposal. <i>New England Journal of Medicine</i> , 2016, 375, 407-409.	27.0	49
231	Non-HDL Cholesterol and Triglycerides. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2220-2228.	2.4	119
232	Sex Differences in Nonculprit Coronary Plaque Microstructures on Frequency-Domain Optical Coherence Tomography in Acute Coronary Syndromes and Stable Coronary Artery Disease. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	2.6	49
233	Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2488-2490.	2.8	4
234	Shining the Light on Calcium in the Catheterization Lab. <i>Circulation Journal</i> , 2016, 80, 1319-1320.	1.6	0

#	ARTICLE	IF	CITATIONS
235	Coronary atheroma progression rates in men and women following high-intensity statin therapy: A pooled analysis of REVERSAL, ASTEROID and SATURN. <i>Atherosclerosis</i> , 2016, 254, 78-84.	0.8	18
236	Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2373.	7.4	813
237	Will Big Data Shine Light at the End of the Tunnel for HDL? <i>Journal of the American College of Cardiology</i> , 2016, 68, 2084-2085.	2.8	4
238	Clinical trials with cholesteryl ester transfer protein inhibitors. <i>Current Opinion in Lipidology</i> , 2016, 27, 545-549.	2.7	15
239	Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 212-217.	3.0	99
240	A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. <i>Pharmacological Research</i> , 2016, 111, 343-356.	7.1	19
241	Non-invasive volumetric assessment of aortic atheroma: a core laboratory validation using computed tomography angiography. <i>International Journal of Cardiovascular Imaging</i> , 2016, 32, 121-129.	1.5	3
242	Management of acute coronary syndrome in the very elderly. <i>Lancet, The</i> , 2016, 387, 1029-1030.	13.7	12
243	Relationship between changes in coronary atherosclerotic plaque burden measured by intravascular ultrasound and cardiovascular disease outcomes: a systematic literature review. <i>Current Medical Research and Opinion</i> , 2016, 32, 1143-1150.	1.9	7
244	The use of polymer-based nanoparticles and nanostructured materials in treatment and diagnosis of cardiovascular diseases: Recent advances and emerging designs. <i>Progress in Polymer Science</i> , 2016, 57, 153-178.	24.7	47
245	Dynamic Self-Referencing Approach to Whispering Gallery Mode Biosensing and Its Application to Measurement within Undiluted Serum. <i>Analytical Chemistry</i> , 2016, 88, 4036-4040.	6.5	37
246	Confirmation of the Intracoronary Near-Infrared Spectroscopy Threshold of Lipid-Rich Plaques That Underlie ST-Segmentâ€Elevation Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1010-1015.	2.4	45
247	Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 744-747.	1.8	47
248	Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 55-65.	2.2	82
249	The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 474-485.	1.8	12
250	The predictive capabilities of a novel cardiovascular magnetic resonance derived marker of cardiopulmonary reserve on established prognostic surrogate markers in patients with pulmonary vascular disease: results of a longitudinal pilot study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 19, 3.	3.3	8
251	Achieving better modulation of coronary atherosclerosis: its understanding, visualization and treatment. <i>Cardiovascular Diagnosis and Therapy</i> , 2016, 6, 280-281.	1.7	9
252	HDL function and subclinical atherosclerosis in juvenile idiopathic arthritis. <i>Cardiovascular Diagnosis and Therapy</i> , 2016, 6, 34-43.	1.7	13

#	ARTICLE	IF	CITATIONS
253	Aortic atheroma burden predicts acute cerebrovascular events after transcatheter aortic valve implantation: insights from volumetric multislice computed tomography analysis. <i>EuroIntervention</i> , 2016, 12, 783-789.	3.2	14
254	Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering. <i>Journal of the Japanese Coronary Association</i> , 2016, 22, 217-227.	0.0	0
255	Abstract 623: Effect of High-intensity Statin Therapy on High-density Lipoprotein (HDL) Subfractions and Regression of Coronary Atheroma: The SATURN Trial. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, .	2.4	0
256	Label-free assessment of endothelial cell metabolic state using autofluorescent microscopy. , 2016, , .		0
257	Lipid Lowering in Patients With Kidney Disease—“ Is It Really That Hard? ”. <i>Circulation Journal</i> , 2015, 79, 976-977.	1.6	0
258	Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. <i>Lipids in Health and Disease</i> , 2015, 14, 98.	3.0	46
259	Statin-induced coronary artery disease regression rates differ in men and women. <i>Current Opinion in Lipidology</i> , 2015, 26, 276-281.	2.7	12
260	Acute high-density lipoprotein therapies. <i>Current Opinion in Lipidology</i> , 2015, 26, 521-525.	2.7	3
261	Relationships between components of metabolic syndrome and coronary intravascular ultrasound atherosclerosis measures in women without obstructive coronary artery disease. <i>Cardiovascular Endocrinology</i> , 2015, 4, 45-52.	0.8	10
262	Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?. <i>Vascular Health and Risk Management</i> , 2015, 11, 203.	2.3	6
263	Position paper Statin intolerance “ an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015, 1, 1-23.	0.9	311
264	To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis. <i>Atherosclerosis</i> , 2015, 241, 450-454.	0.8	17
265	Atheroma Progression in Hyporesponders to Statin Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 990-995.	2.4	58
266	CYP-mediated drug-drug interactions with evacetrapib, an investigational CETP inhibitor: <i>in vitro</i> prediction and clinical outcome. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1388-1398.	2.4	9
267	Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2201-2210.	2.8	105
268	Optical coherence tomography for serial <i>in vivo</i> imaging of aortic plaque in the rabbit: a preliminary experience. <i>Open Heart</i> , 2015, 2, e000314.	2.3	4
269	Cholesterol Crystals Associate With Coronary Plaque Vulnerability <i>In Vivo</i> . <i>Journal of the American College of Cardiology</i> , 2015, 65, 630-632.	2.8	52
270	Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk?. <i>Circulation</i> , 2015, 132, 423-432.	1.6	24

#	ARTICLE	IF	CITATIONS
271	Favorable Impact on LDL Particle Size in Response to Treatment With Pioglitazone is Associated With Less Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2015, 66, 328-329.	2.8	7
272	Response to Comment on Stegman et al. High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights From SATURN. <i>Diabetes Care</i> 2014;37:3114-3120. <i>Diabetes Care</i> , 2015, 38, e28-e29.	8.6	2
273	Redox biomarkers in cardiovascular medicine. <i>European Heart Journal</i> , 2015, 36, 1576-1582.	2.2	61
274	Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 935-955.	2.4	117
275	Lipid Biomarkers and Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1296-1297.	2.8	3
276	Impact of Statins on Serial Coronary Calcification During Atheroma Progression and Regression. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1273-1282.	2.8	467
277	Men and women – similar but not identical: insights into LDL-lowering therapy in women from the Cholesterol Treatment Trialists Collaboration. <i>Future Cardiology</i> , 2015, 11, 511-515.	1.2	3
278	Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. <i>Atherosclerosis</i> , 2015, 243, 553-559.	0.8	3
279	Plaque vulnerability at non-culprit lesions in obese patients with coronary artery disease: Frequency-domain optical coherence tomography analysis. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1331-1339.	1.8	7
280	Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. <i>Atherosclerosis</i> , 2015, 242, 490-495.	0.8	43
281	Statins and CETP Inhibitors: Anacetrapib and Evacetrapib: The Last Hope?. , 2015, , 65-71.		1
282	Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. <i>American Heart Journal</i> , 2015, 170, 1061-1069.	2.7	74
283	Near-Infrared Spectroscopy Enhances Intravascular Ultrasound Assessment of Vulnerable Coronary Plaque. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2423-2431.	2.4	48
284	Coronary atheroma composition and its association with segmental endothelial dysfunction in non-ST segment elevation myocardial infarction: novel insights with radiofrequency (iMAP) intravascular ultrasonography. <i>International Journal of Cardiovascular Imaging</i> , 2015, 31, 247-257.	1.5	5
285	Ongoing challenges for pharmacotherapy for dyslipidemia. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 347-356.	1.8	6
286	Inflammation, plaque progression and vulnerability: evidence from intravascular ultrasound imaging. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 280-9.	1.7	16
287	Coronary artery wall shear stress is associated with endothelial dysfunction and expansive arterial remodelling in patients with coronary artery disease. <i>EuroIntervention</i> , 2015, 10, 1440-1448.	3.2	21
288	Examining controversies and new frontiers in lipid management. <i>Clinical Lipidology</i> , 2014, 9, 587-595.	0.4	0

#	ARTICLE	IF	CITATIONS
289	Left main coronary arterial endothelial function and heterogenous segmental epicardial vasomotor reactivity in vivo: novel insights with intravascular ultrasonography. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 1270-1280.	1.2	1
290	Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 252.	7.4	270
291	Targeting obesity, diabetes and the metabolic syndrome: are we trying to close the barn door after the horse bolted?. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 279-280.	1.5	0
292	Imaging of atherosclerotic plaques in obesity: excessive fat accumulation, plaque progression and vulnerability. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1471-1489.	1.5	6
293	Evolving targets for lipid-modifying therapy. <i>EMBO Molecular Medicine</i> , 2014, 6, 1215-1230.	6.9	11
294	Effect of Alogliptazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1515.	7.4	206
295	Update in Therapeutic Approaches to Plaque Stabilization. <i>Current Atherosclerosis Reports</i> , 2014, 16, 392.	4.8	4
296	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. <i>European Heart Journal</i> , 2014, 35, 960-968.	2.2	270
297	High-Risk Coronary Atheroma. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1134-1140.	2.8	32
298	Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 380-388.	1.2	139
299	Impact of Baseline Lipoprotein and C-Reactive Protein Levels on Coronary Atheroma Regression Following High-Intensity Statin Therapy. <i>American Journal of Cardiology</i> , 2014, 114, 1465-1472.	1.6	42
300	Is Lp(a) Ready for Prime Time?. <i>Journal of the American College of Cardiology</i> , 2014, 64, 861-862.	2.8	2
301	Inflammation and Neovascularization Intertwined in Atherosclerosis. <i>Circulation</i> , 2014, 130, 786-794.	1.6	47
302	Lipid pharmacotherapy for treatment of atherosclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1119-1125.	1.8	13
303	Relation of High-Density Lipoprotein Cholesterol:Apolipoprotein A-I Ratio to Progression of Coronary Atherosclerosis in Statin-Treated Patients. <i>American Journal of Cardiology</i> , 2014, 114, 681-685.	1.6	18
304	High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights From SATURN. <i>Diabetes Care</i> , 2014, 37, 3114-3120.	8.6	50
305	Sex-Related Differences of Coronary Atherosclerosis Regression Following Maximally Intensive Statin Therapy. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 1013-1022.	5.3	54
306	Antiatherosclerotic Effects of Long-Term Maximally Intensive Statin Therapy After Acute Coronary Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2465-2472.	2.4	41

#	ARTICLE	IF	CITATIONS
307	Progression of coronary atherosclerosis in stable patients with ultrasonic features of high-risk plaques. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 1035-1041.	1.2	25
308	Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1298-1306.	2.4	59
309	Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: Insights from intravascular ultrasound. <i>Atherosclerosis</i> , 2014, 232, 377-383.	0.8	40
310	The impact of lumen size and microvascular resistance on Fourier-domain optical coherence tomography (FD-OCT) coronary measurements. <i>International Journal of Cardiology</i> , 2014, 174, 210-211.	1.7	1
311	Eprotrirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 455-463.	11.4	84
312	Frequency-Domain Optical Coherence Tomographic Analysis of Plaque Microstructures at Nonculprit Narrowings in Patients Receiving Potent Statin Therapy. <i>American Journal of Cardiology</i> , 2014, 114, 549-554.	1.6	37
313	Achievement of combined goals of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol with three different statins: Results from VOYAGER. <i>IJC Metabolic & Endocrine</i> , 2014, 5, 61-66.	0.5	1
314	New Drugs for HDL-C Disorders: The Beginning. <i>Current Medicinal Chemistry</i> , 2014, 21, 2947-2951.	2.4	3
315	Controversies on HDL: Should it be a Target Biomarker in Patients with Lipid Disorders?. <i>Current Vascular Pharmacology</i> , 2014, 12, 649-652.	1.7	1
316	Niacin's effect on cardiovascular risk: Have we finally learned our lesson?. <i>Cleveland Clinic Journal of Medicine</i> , 2014, 81, 275-277.	1.3	3
317	Spotty calcification and plaque vulnerability in vivo: frequency-domain optical coherence tomography analysis. <i>Cardiovascular Diagnosis and Therapy</i> , 2014, 4, 460-9.	1.7	63
318	Residual Risk and Biology of the Disease: Implications for Plaque Imaging. <i>Contemporary Cardiology</i> , 2014, , 1-21.	0.1	1
319	Atherosclerotic Plaque Imaging for Evaluation of HDL Targeting Therapy. <i>Journal of the Japanese Coronary Association</i> , 2014, 20, 282-294.	0.0	0
320	Monitoring the Progression and Regression of Coronary Atherosclerosis with Intravascular Ultrasound. <i>Contemporary Cardiology</i> , 2014, , 67-79.	0.1	0
321	Evaluation of the dual peroxisome proliferator-activated receptor α/β agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial. <i>American Heart Journal</i> , 2013, 166, 429-434.e1.	2.7	39
322	A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial). <i>Clinical Therapeutics</i> , 2013, 35, 1400-1411.e3.	2.5	94
323	Left Main Coronary Atherosclerosis Progression, Constrictive Remodeling, and Clinical Events. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 29-35.	2.9	36
324	Detection by Near-Infrared Spectroscopy of Large Lipid Core Plaques at Culprit Sites in Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 838-846.	2.9	169

#	ARTICLE	IF	CITATIONS
325	Cardiac Allograft Vasculopathy by Intravascular Ultrasound in Heart Transplant Patients. JACC: Heart Failure, 2013, 1, 389-399.	4.1	110
326	Intracoronary Optical Coherence Tomography. Journal of the American College of Cardiology, 2013, 62, 1759-1760.	2.8	0
327	Lipidomics: Opportunities to Identify New Causal Mechanisms and Therapeutics for Atherosclerosis. Current Cardiovascular Risk Reports, 2013, 7, 60-65.	2.0	0
328	Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <math><70\text{ mg/dl}</math> or a 50% reduction in high-risk patients: Results from VOYAGER. Atherosclerosis, 2013, 228, 265-269.	0.8	20
329	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy: A meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacological Research, 2013, 72, 35-44.	7.1	90
330	Exploring coronary atherosclerosis with intravascular imaging. International Journal of Cardiology, 2013, 168, 670-679.	1.7	44
331	Epanova and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy. Future Cardiology, 2013, 9, 177-186.	1.2	12
332	Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Current Medical Research and Opinion, 2013, 29, 435-451.	1.9	36
333	Factors underlying regression of coronary atheroma with potent statin therapy. European Heart Journal, 2013, 34, 1818-1825.	2.2	61
334	Coronary Endothelium-Dependent Vasoreactivity and Atheroma Volume in Subjects With Stable, Minimal Angiographic Disease Versus Non-ST-Segment Elevation Myocardial Infarction. Circulation: Cardiovascular Imaging, 2013, 6, 674-682.	2.6	8
335	Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. European Heart Journal, 2013, 34, 3182-3190.	2.2	86
336	Imaging coronary atherosclerosis: is there space for magnetic resonance imaging?. Expert Review of Cardiovascular Therapy, 2013, 11, 383-385.	1.5	1
337	Is It Time for HDL to Change Its Tune?. Circulation, 2013, 128, 1175-1176.	1.6	4
338	Effect of Aliskiren on Progression of Coronary Disease in Patients With Prehypertension. JAMA - Journal of the American Medical Association, 2013, 310, 1135.	7.4	67
339	Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: An analysis from the VOYAGER database. European Journal of Preventive Cardiology, 2013, 20, 1080-1087.	1.8	22
340	Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus. European Journal of Preventive Cardiology, 2013, 20, 209-217.	1.8	26
341	C-Reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate With Coronary Atheroma Regression and Cardiovascular Events After Maximally Intensive Statin Therapy. Circulation, 2013, 128, 2395-2403.	1.6	109
342	Imaging Progression of Coronary Atherosclerosis. Circulation Journal, 2013, 77, 3-10.	1.6	9

#	ARTICLE	IF	CITATIONS
343	Translational Application of In Vivo Imaging and Analysis of Atherosclerotic Plaque Vulnerability Assessment. <i>Recent Patents on Medical Imaging</i> , 2013, 3, 14-26.	0.1	0
344	Progression of coronary atherosclerosis in African-American patients. <i>Cardiovascular Diagnosis and Therapy</i> , 2013, 3, 161-9.	1.7	7
345	Peroxisome proliferator-activated receptor (PPAR α/β) agonists as a potential target to reduce cardiovascular risk in diabetes. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 89-94.	2.0	19
346	Predicting the Future. <i>Circulation</i> , 2012, 126, 161-162.	1.6	3
347	Coronary β_2 -adrenoreceptors mediate endothelium-dependent vasoreactivity in humans: novel insights from an in vivo intravascular ultrasound study. <i>European Heart Journal</i> , 2012, 33, 495-504.	2.2	36
348	Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 367, 2089-2099.	27.0	1,754
349	Optimizing Outcomes During Left Main Percutaneous Coronary Intervention With Intravascular Ultrasound and Fractional Flow Reserve. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 697-707.	2.9	72
350	Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 349-358.	2.6	14
351	The emerging role of plasma lipidomics in cardiovascular drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 63-72.	5.0	20
352	Relationship of antihypertensive treatment to plasma markers of vascular inflammation and remodeling in the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis study. <i>American Heart Journal</i> , 2012, 163, 735-740.	2.7	10
353	"Framing" the Vessel. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1038-1039.	2.8	5
354	The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 307 T <i>Cardiology</i> , 2012, 59, 2065-2067.	2.8	20
355	Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1592-1597.	2.8	164
356	Suspected Hypersensitivity Reaction Following Drug-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, e21-e23.	2.9	4
357	Variations in Coronary Lumen Dimensions Measured In Vivo. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 123-124.	5.3	2
358	Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?. <i>Progress in Lipid Research</i> , 2012, 51, 314-324.	11.6	187
359	Current imaging modalities for atherosclerosis. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 457-471.	1.5	7
360	ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 181-187.	2.6	80

#	ARTICLE	IF	CITATIONS
361	Evacetrapib. <i>Current Cardiology Reports</i> , 2012, 14, 245-250.	2.9	13
362	The Distinctive Nature of Atherosclerotic Vascular Disease in Diabetes: Pathophysiological and Morphological Insights. <i>Current Diabetes Reports</i> , 2012, 12, 280-285.	4.2	24
363	Intracoronary IVUS for Evaluation of Atherosclerosis Progression. <i>Current Cardiovascular Imaging Reports</i> , 2012, 5, 239-248.	0.6	0
364	Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 71-75.	2.6	39
365	Is niacin ineffective? Or did AIM-HIGH miss its target?. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, 38-43.	1.3	34
366	Abstract 479: Juvenile Idiopathic Arthritis Does Not Impair ABCA-1 and SR-B1-Mediated Cholesterol Efflux Capacity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, .	2.4	0
367	ETC-216 for coronary artery disease. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 387-394.	3.1	25
368	Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients. <i>Journal of the American College of Cardiology</i> , 2011, 57, 153-159.	2.8	106
369	Peripheral Arterial Disease and Progression of Coronary Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1220-1225.	2.8	84
370	Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1111-1119.	2.8	161
371	Will apoA-I-based therapies step up to cure coronary artery disease?. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1367-1370.	1.5	0
372	Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. <i>New England Journal of Medicine</i> , 2011, 365, 2078-2087.	27.0	731
373	Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1383-1390.	1.5	7
374	Intravascular imaging of vulnerable coronary plaque: current and future concepts. <i>Nature Reviews Cardiology</i> , 2011, 8, 131-139.	13.7	84
375	Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 <i>Current Medical Research and Opinion</i> , 2011, 27, 1119-1129.	1.9	43
376	The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins. <i>Atherosclerosis</i> , 2011, 217, 395-400.	0.8	63
377	Editorial introductions. <i>Current Opinion in Rheumatology</i> , 2011, 23, vii-viii.	4.3	0
378	High-Density Lipoprotein: Is the Good Cholesterol Turning Bad?. <i>Current Cardiovascular Risk Reports</i> , 2011, 5, 18-28.	2.0	2

#	ARTICLE	IF	CITATIONS
379	Apo A-I Modulating Therapies. <i>Current Cardiology Reports</i> , 2011, 13, 537-543.	2.9	5
380	Insights From a Virtual World – Editorials published in <i>JACC: Cardiovascular Interventions</i> reflect the views of the authors and do not necessarily represent the views of <i>JACC: Cardiovascular Interventions</i> or the American College of Cardiology. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 511-512.	2.9	0
381	Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2099-109.	7.4	374
382	Risk Prediction with Serial Myeloperoxidase Monitoring in Patients with Acute Chest Pain. <i>Clinical Chemistry</i> , 2011, 57, 1762-1770.	3.2	41
383	A Prospective, Randomized Trial of Single-Drug Versus Dual-Drug Immunosuppression in Heart Transplantation. <i>Circulation: Heart Failure</i> , 2011, 4, 129-137.	3.9	62
384	Plasma Myeloperoxidase Predicts Incident Cardiovascular Risks in Stable Patients Undergoing Medical Management for Coronary Artery Disease. <i>Clinical Chemistry</i> , 2011, 57, 33-39.	3.2	86
385	Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies. <i>EuroIntervention</i> , 2011, 6, 1123-1130.	3.2	137
386	Assessment of Plaque Burden and Plaque Composition Using Intravascular Ultrasound. , 2011, , 483-493.		0
387	Inflammatory Markers and Novel Risk Factors. , 2011, , 107-123.		0
388	Biomarkers of inflammation and oxidative stress in atherosclerosis. <i>Biomarkers in Medicine</i> , 2010, 4, 361-373.	1.4	54
389	Intracoronary Ultrasound in Assessing Efficacy of Cardiovascular Drugs. <i>Current Cardiovascular Imaging Reports</i> , 2010, 3, 190-196.	0.6	0
390	Statin Effects on Both Low-Density Lipoproteins and High-Density Lipoproteins: Is There a Dual Benefit?. <i>Current Atherosclerosis Reports</i> , 2010, 12, 14-19.	4.8	4
391	Lessons from Coronary Intravascular Ultrasound on the Importance of Raising High-Density Lipoprotein Cholesterol. <i>Current Atherosclerosis Reports</i> , 2010, 12, 301-307.	4.8	8
392	Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER). <i>American Journal of Cardiology</i> , 2010, 105, 69-76.	1.6	206
393	Plaque Progression in Coronary Arteries With Minimal Luminal Obstruction in Intravascular Ultrasound Atherosclerosis Trials. <i>American Journal of Cardiology</i> , 2010, 105, 1679-1683.	1.6	13
394	Comparison of Rates of Progression of Coronary Atherosclerosis in Patients With Diabetes Mellitus Versus Those With the Metabolic Syndrome. <i>American Journal of Cardiology</i> , 2010, 105, 1735-1739.	1.6	32
395	An Intravascular Ultrasound Analysis in Women Experiencing Chest Pain in the Absence of Obstructive Coronary Artery Disease: A Substudy from the National Heart, Lung and Blood Institute – Sponsored Women’s Ischemia Syndrome Evaluation (WISE). <i>Journal of Interventional Cardiology</i> , 2010, 23, 511-519.	1.2	162
396	Reducing cardiovascular risk in patients with type 2 diabetes mellitus. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, s1-s1.	2.8	0

#	ARTICLE	IF	CITATIONS
397	Strategies for the development of new PPAR agonists in diabetes. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, s32-s37.	2.8	4
398	Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. <i>Journal of Lipid Research</i> , 2010, 51, 1546-1553.	4.2	198
399	Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. <i>Journal of Lipid Research</i> , 2010, 51, 3055-3061.	4.2	76
400	Subclinical Myocardial Necrosis and Cardiovascular Risk in Stable Patients Undergoing Elective Cardiac Evaluation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 634-640.	2.4	24
401	Diabetic dyslipidemia: extending the target beyond LDL cholesterol. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, s20-s24.	2.8	11
402	The Metabolic Syndrome, Its Component Risk Factors, and Progression of Coronary Atherosclerosis. <i>Archives of Internal Medicine</i> , 2010, 170, 478.	3.8	114
403	Future requirement for arterial wall imaging modalities in the evaluation of novel anti-atherosclerotic therapies. <i>Current Medical Research and Opinion</i> , 2010, 26, 753-757.	1.9	1
404	Findings of clinical trials that evaluate the impact of medical therapies on progression of atherosclerosis. <i>Current Medical Research and Opinion</i> , 2010, 26, 745-751.	1.9	1
405	Rationale and approach to evaluation of the impact of medical therapies on progression of atherosclerosis with arterial wall imaging. <i>Current Medical Research and Opinion</i> , 2010, 26, 737-744.	1.9	1
406	Clinical Predictors of Plaque Progression Despite Very Low Levels of Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2736-2742.	2.8	143
407	Intravascular Ultrasound-Derived Measures of Coronary Atherosclerotic Plaque Burden and Clinical Outcome. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2399-2407.	2.8	405
408	Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. <i>Lancet</i> , The, 2010, 375, 1875-1884.	13.7	788
409	High-Density Lipoprotein and Progression Rate of Atherosclerosis in Intravascular Ultrasound Trials. <i>American Journal of Cardiology</i> , 2009, 104, 16E-21E.	1.6	7
410	Attenuated Plaque at Nonculprit Lesions in Patients Enrolled in Intravascular Ultrasound Atherosclerosis Progression Trials. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 672-678.	2.9	33
411	Low Levels of Low-Density Lipoprotein Cholesterol and Blood Pressure and Progression of Coronary Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1110-1115.	2.8	63
412	Pharmacologic therapy for coronary atherosclerosis in patients with Type 2 diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 85-93.	1.5	2
413	Effect of lipid-modifying therapies on the functional quality of high-density lipoproteins: implications for drug development. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 753-761.	5.0	2
414	Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins. <i>Atherosclerosis</i> , 2009, 204, 424-428.	0.8	81

#	ARTICLE	IF	CITATIONS
415	Myeloperoxidase, modified lipoproteins, and atherogenesis. <i>Journal of Lipid Research</i> , 2009, 50, S346-S351.	4.2	168
416	Relationship between LDL, HDL, blood pressure and atheroma progression in the coronaries. <i>Current Opinion in Lipidology</i> , 2009, 20, 491-496.	2.7	16
417	Invasive Imaging Modalities and Atherosclerosis: The Role of Intravascular Ultrasound. , 2009, , 410-419.		1
418	Intravascular Ultrasound. , 2009, , 83-93.		0
419	Rosuvastatin and progression of atherosclerosis. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 925-933.	1.5	8
420	Brain Natriuretic Peptides as Biomarkers for Atherosclerosis. <i>Preventive Cardiology</i> , 2008, 11, 172-176.	1.1	10
421	Effect of Diabetes on Progression of Coronary Atherosclerosis and Arterial Remodeling. <i>Journal of the American College of Cardiology</i> , 2008, 52, 255-262.	2.8	296
422	Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. <i>Atherosclerosis</i> , 2008, 196, 240-247.	0.8	79
423	Relationship of Paraoxonase 1 (PON1) Gene Polymorphisms and Functional Activity With Systemic Oxidative Stress and Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1265.	7.4	463
424	Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1547.	7.4	367
425	Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography. <i>Circulation</i> , 2008, 117, 2458-2466.	1.6	186
426	Response to Letter Regarding Article, "Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial Infarct". <i>Circulation</i> , 2008, 118, .	1.6	0
427	Response to Letters Regarding Article, "Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography: A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound" Derived Coronary Atheroma Burden". <i>Circulation</i> , 2008, 118, .	1.6	0
428	Homocysteine Levels, Paraoxonase 1 (PON1) Activity, and Cardiovascular Risk" Reply. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 168.	7.4	2
429	Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1561.	7.4	782
430	Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis. <i>Circulation</i> , 2008, 118, 2506-2514.	1.6	200
431	High-density lipoprotein and atheroma monitoring. <i>Current Opinion in Cardiology</i> , 2008, 23, 386-392.	1.8	1
432	Atherosclerotic plaque reduction: Blood pressure, dyslipidemia, atherothrombosis. <i>Drugs of Today</i> , 2008, 44, 711.	1.1	5

#	ARTICLE	IF	CITATIONS
433	HDL: still a target for new therapies?. <i>Current Opinion in Investigational Drugs</i> , 2008, 9, 950-6.	2.3	7
434	Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial Infarction. <i>Circulation</i> , 2007, 116, 2315-2324.	1.6	85
435	Exploring the natural history of atherosclerosis with intravascular ultrasound. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 295-306.	1.5	7
436	Effect of Torcetrapib on the Progression of Coronary Atherosclerosis. <i>New England Journal of Medicine</i> , 2007, 356, 1304-1316.	27.0	921
437	Effects of a Potent and Selective PPAR- α Agonist in Patients With Atherogenic Dyslipidemia or Hypercholesterolemia. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1362.	7.4	121
438	Atherosclerosis imaging in drug development. <i>Expert Opinion on Drug Discovery</i> , 2007, 2, 1241-1250.	5.0	0
439	Impact of statins on atherosclerotic plaque. <i>Future Cardiology</i> , 2007, 3, 157-164.	1.2	1
440	Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 1180.	7.4	1,143
441	Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 499.	7.4	654
442	β -Blockers and Progression of Coronary Atherosclerosis: Pooled Analysis of 4 Intravascular Ultrasonography Trials. <i>Annals of Internal Medicine</i> , 2007, 147, 10.	3.9	83
443	New targets of high-density lipoprotein therapy. <i>Current Opinion in Lipidology</i> , 2007, 18, 421-426.	2.7	21
444	Impact Of Statin Therapy On The Artery Wall In The Low-Risk Patient: Implications From The METEOR Study. <i>Future Lipidology</i> , 2007, 2, 595-601.	0.5	0
445	Coronary Angiography for Follow-up of Heart Transplant Recipients: Insights From TIMI Frame Count and TIMI Myocardial Perfusion Grade. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 593-597.	0.6	14
446	Coronary Artery Calcification and Changes in Atheroma Burden in Response to Established Medical Therapies. <i>Journal of the American College of Cardiology</i> , 2007, 49, 263-270.	2.8	125
447	Rate of Progression of Coronary Atherosclerotic Plaque in Women. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1546-1551.	2.8	71
448	Protein carbamylation links inflammation, smoking, uremia and atherogenesis. <i>Nature Medicine</i> , 2007, 13, 1176-1184.	30.7	601
449	Comparison of Coronary Atherosclerotic Volume in Patients With Glomerular Filtration Rates ≤ 60 Versus >60 ml/min/1.73 m ² : A Meta-Analysis of Intravascular Ultrasound Studies. <i>American Journal of Cardiology</i> , 2007, 99, 813-816.	1.6	28
450	Atherosclerosis regression: Is low-density lipoprotein or high-density lipoprotein the answer?. <i>Current Atherosclerosis Reports</i> , 2007, 9, 266-273.	4.8	11

#	ARTICLE	IF	CITATIONS
451	Intensive lipid lowering in the cardiovascular patient: Who, how low, and for how long?. Current Cardiovascular Risk Reports, 2007, 1, 290-295.	2.0	0
452	Abstract 684: Changes in Levels of High Density Lipoprotein Cholesterol Predict the Impact of Torcetrapib on Progression of Coronary Atherosclerosis: Insights from ILLUSTRATE. Circulation, 2007, 116, .	1.6	6
453	Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis. New England Journal of Medicine, 2006, 354, 1253-1263.	27.0	368
454	Paradoxical increase in lumen size during progression of coronary atherosclerosis: Observations from the REVERSAL trial. Atherosclerosis, 2006, 189, 229-235.	0.8	42
455	Intravascular Ultrasound in the Current Percutaneous Coronary Intervention Era. Cardiology Clinics, 2006, 24, 163-173.	2.2	7
456	Relationship Between Atheroma Regression and Change in Lumen Size After Infusion of Apolipoprotein A-I Milano. Journal of the American College of Cardiology, 2006, 47, 992-997.	2.8	141
457	Relationship Between Cardiovascular Risk Factors and Atherosclerotic Disease Burden Measured by Intravascular Ultrasound. Journal of the American College of Cardiology, 2006, 47, 1967-1975.	2.8	142
458	Consumption of Saturated Fat Impairs the Anti-Inflammatory Properties of High-Density Lipoproteins and Endothelial Function. Journal of the American College of Cardiology, 2006, 48, 715-720.	2.8	180
459	Effects of Normal, Pre-Hypertensive, and Hypertensive Blood Pressure Levels on Progression of Coronary Atherosclerosis. Journal of the American College of Cardiology, 2006, 48, 833-838.	2.8	168
460	Intravascular ultrasound assessment of novel antiatherosclerotic therapies: Rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study. American Heart Journal, 2006, 152, 67-74.	2.7	27
461	Static and serial assessments of coronary arterial remodeling are discordant: An intravascular ultrasound analysis from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. American Heart Journal, 2006, 152, 544-550.	2.7	26
462	Monitoring pharmaceutical interventions with IVUS. , 2006, , 451-463.		0
463	Compensatory enlargement of human coronary arteries during progression of atherosclerosis is unrelated to atheroma burden: serial intravascular ultrasound observations from the REVERSAL trial. European Heart Journal, 2006, 27, 1664-1670.	2.2	31
464	The ACTIVATE study: lessons for the future of atherosclerotic therapy. Future Lipidology, 2006, 1, 421-428.	0.5	0
465	Studying Coronary Plaque Regression with IVUS. Journal of Interventional Cardiology, 2006, 19, 345-345.	1.2	1
466	Application of intravascular ultrasound in anti-atherosclerotic drug development. Nature Reviews Drug Discovery, 2006, 5, 485-492.	46.4	43
467	High-density lipoproteins: an emerging target in the prevention of cardiovascular disease. Cell Research, 2006, 16, 799-808.	12.0	19
468	Recent trends in coronary intravascular ultrasound: Tracking atherosclerosis, pursuit of vulnerable plaques, and beyond. Journal of Nuclear Cardiology, 2006, 13, 91-96.	2.1	6

#	ARTICLE	IF	CITATIONS
469	Effects of Obesity on Lipid-Lowering, Anti-Inflammatory, and Antiatherosclerotic Benefits of Atorvastatin or Pravastatin in Patients With Coronary Artery Disease (from the REVERSAL Study). <i>American Journal of Cardiology</i> , 2006, 97, 1553-1557.	1.6	64
470	Emerging Role of Intravascular Ultrasound in the Assessment of Experimental Anti-Atherosclerotic Therapies. <i>Current Medicinal Chemistry</i> , 2006, 13, 1727-1734.	2.4	3
471	Intravascular Ultrasound in Cardiovascular Medicine. <i>Circulation</i> , 2006, 114, e55-9.	1.6	49
472	Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1556.	7.4	1,759
473	Determinants of Arterial Wall Remodeling During Lipid-Lowering Therapy. <i>Circulation</i> , 2006, 113, 2826-2834.	1.6	145
474	The ASTEROID trial: coronary plaque regression with high-dose statin therapy. <i>Future Cardiology</i> , 2006, 2, 651-654.	1.2	21
475	Coronary atherosclerosis can regress with very intensive statin therapy.. <i>Cleveland Clinic Journal of Medicine</i> , 2006, 73, 937-944.	1.3	40
476	High-density lipoproteins as therapeutic targets. <i>Current Opinion in Lipidology</i> , 2005, 16, 345-349.	2.7	36
477	Effect of Atorvastatin (80 mg/day) Versus Pravastatin (40 mg/day) on Arterial Remodeling at Coronary Branch Points (from the REVERSAL Study). <i>American Journal of Cardiology</i> , 2005, 96, 1636-1639.	1.6	14
478	Formation of Dysfunctional High-Density Lipoprotein by Myeloperoxidase. <i>Trends in Cardiovascular Medicine</i> , 2005, 15, 212-219.	4.9	138
479	Reconstituted High-Density Lipoproteins Inhibit the Acute Pro-Oxidant and Proinflammatory Vascular Changes Induced by a Periarterial Collar in Normocholesterolemic Rabbits. <i>Circulation</i> , 2005, 111, 1543-1550.	1.6	275
480	Impact of Short-Term Administration of High-Density Lipoproteins and Atorvastatin on Atherosclerosis in Rabbits. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2416-2421.	2.4	146
481	Strategies to promote HDL-C: an emerging therapeutic target. <i>European Heart Journal</i> , 2005, 26, 853-855.	2.2	10
482	Myeloperoxidase and Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1102-1111.	2.4	653
483	Quantification of Nitrotyrosine Levels Using a Benchtop Ion Trap Mass Spectrometry Method. <i>Methods in Enzymology</i> , 2005, 396, 245-266.	1.0	23
484	The Emerging Role of Lipoproteins in Atherogenesis: Beyond LDL Cholesterol. <i>Seminars in Vascular Medicine</i> , 2004, 4, 187-195.	2.1	41
485	Antiinflammatory Properties of HDL. <i>Circulation Research</i> , 2004, 95, 764-772.	4.5	1,170
486	The role of myeloperoxidase in the pathogenesis of coronary artery disease. <i>Japanese Journal of Infectious Diseases</i> , 2004, 57, S21-2.	1.2	19

#	ARTICLE	IF	CITATIONS
487	Pain in the neck. Lancet, The, 2003, 361, 1700.	13.7	6
488	Papillary fibroelastoma, a rare but potentially treatable cause of embolic stroke: Report of three cases. Heart Lung and Circulation, 2001, 10, 105-107.	0.4	7
489	Current and emerging therapies in atheroprotection. , 0, , 79-102.		0